Accessibility navigation


Low dose Btk inhibitors selectively block platelet activation by CLEC-2

Nicolson, P. L., Nock, S. H., Hinds, J., Garcia-Quintanilla, L., Smith, C. W., Campos, J., Brill, A., Pike, J. A., Khan, A. O., Poulter, N. S., Kavanagh, D. M., Watson, S., Watson, C. N., Clifford, H., Huissoon, A. P., Pollitt, A. Y., Eble, J. A., Pratt, G., Watson, S. P. and Hughes, C. E. ORCID: https://orcid.org/0000-0002-9790-5820 (2020) Low dose Btk inhibitors selectively block platelet activation by CLEC-2. Haematologica, 105 (1). ISSN 1592-8721

[img]
Preview
Text (Open Access) - Published Version
· Available under License Creative Commons Attribution Non-commercial.
· Please see our End User Agreement before downloading.

1MB
[img] Text - Accepted Version
· Restricted to Repository staff only

9MB

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.3324/haematol.2019.218545

Abstract/Summary

Inhibitors of the tyrosine kinase Btk have been proposed as novel antiplatelet agents. In this study we show that low concentrations of the Btk inhibitor ibrutinib block CLEC-2-mediated activation and tyrosine phosphorylation including Syk and PLCγ2 in human platelets. Activation is also blocked in patients with X-linked agammaglobulinaemia (XLA) caused by a deficiency or absence of Btk. In contrast, the response to GPVI is delayed in the presence of low concentrations of ibrutinib or in patients with XLA, and tyrosine phosphorylation of Syk is preserved. A similar set of results is seen with the second-generation inhibitor, acalabrutinib. The differential effect of Btk inhibition in CLEC-2 relative to GPVI signalling is explained by the positive feedback role involving Btk itself, as well as ADP and thromboxane A2 mediated activation of P2Y12 and TP receptors, respectively. This feedback role is not seen in mouse platelets and, consistent with this, CLEC-2-mediated activation is blocked by high but not by low concentrations of ibrutinib. Nevertheless, thrombosis was absent in 8 out of 13 mice treated with ibrutinib. These results show that Btk inhibitors selectively block activation of human platelets by CLEC-2 relative to GPVI suggesting that they can be used at ‘low dose’ in patients to target CLEC-2 in thrombo-inflammatory disease.

Item Type:Article
Refereed:Yes
Divisions:Life Sciences > School of Biological Sciences > Biomedical Sciences
ID Code:88356
Publisher:Ferrata Storti Foundation

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation